Allt inom mfn-ext-nq
Nomination Committee for the 2026 Annual General Meeting in Nanexa AB (publ)
The Nomination Committee for the Annual General Meeting 2026 in Nanexa AB (publ) has been appointed.
Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation
- Nanexa’s atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.
- Significantly smoother plasma concentration curve could mitigate many common side effects of GLP-1 drugs.